Beactica
Desconocido
SciLifeLab PULSE: SciLifeLab Programme for fUture Leaders in life SciencE
SciLifeLab PULSE is a MSCA-COFUND postdoctoral programme of excellence in Life Sciences coordinated by the Swedish research infrastructure S...
2024-09-16 - 2030-08-31 | Financiado
2024-09-16 - 2030-08-31 | Financiado
UBIMOTIF: Short linear interaction motifs as specificity determinants in the ubiquitin system discovery mec...
BEACTICA THERAPEUTICS AB
participó en un
H2020:
H2020-MSCA-ITN-2019
A major challenge is the lack of therapeutic approaches for numerous human diseases, which poses a societal challenge. The ubiquitin system...
2019-08-09 - 2024-05-31 | Financiado
2019-08-09 - 2024-05-31 | Financiado
EpiGlioT: Epigenetic Glioblastoma Therapeutics
BEACTICA THERAPEUTICS AB
tramitó un
H2020:
H2020-EIC-SMEInst-2018-2020
The goal of this project is to develop a successful treatment that combats the progression of glioblastoma and improve patients’ quality of...
2018-06-01 - 2018-09-30 | Financiado
2018-06-01 - 2018-09-30 | Financiado
FRAGNET: FRAGments training NETwork
BEACTICA THERAPEUTICS AB
participó en un
H2020:
H2020-MSCA-ITN-2015
The promise of more efficient lead discovery is fuelling the enthusiasm for fragment-based lead discovery (FBLD). In this approach, highly s...
2015-08-11 - 2020-02-29 | Financiado
2015-08-11 - 2020-02-29 | Financiado
ENABLE: European Gram Negative Antibacterial Engine
BEACTICA THERAPEUTICS AB
participó en un
FP6:
The intensive use and misuse of antibiotics has resulted in some level of antibiotic resistance in essentially all human bacterial pathogens...
2014-02-01 - 2020-01-31 | Financiado
2014-02-01 - 2020-01-31 | Financiado
SYNSYS: Synaptic Systems dissecting brain function in health and disease
BEACTICA THERAPEUTICS AB
participó en un
FP7:
Major disorders of the Central Nervous System (CNS) affect one in three people in the developed world, often seriously disable the affected...
Financiado
Financiado
NEUROCYPRES: Neurotransmitter Cys loop receptors structure function and disease
BEACTICA THERAPEUTICS AB
participó en un
FP7:
Cys-loop receptors (CLRs) form a superfamily of structurally related neurotransmitter-gated ion channels, comprising nicotinic acetylcholine...
Financiado
Financiado
BRAINTRAIN: BrainTrain Integrative neuroscience school on brain function and disease
BEACTICA THERAPEUTICS AB
participó en un
FP7:
Brain disorders, in particular neurodegenerative diseases and mental illnesses are among the most prevalent and debilitating diseases. Becau...
Financiado
Financiado
ENABLE: European Gram Negative Antibacterial Engine
BEACTICA THERAPEUTICS AB
participó en un
FP7:
The intensive use and misuse of antibiotics has resulted in some level of antibiotic resistance in essentially all human bacterial pathogens...
Financiado
Financiado
FLUCURE: Development of novel antiviral drugs against Influenza
BEACTICA THERAPEUTICS AB
participó en un
FP7:
Influenza viruses cause a highly contagious respiratory disease in both humans and animals. Typically, influenza spreads worldwide in season...
Financiado
Financiado
FLUDRUGSTRATEGY: Combating influenza using a novel drug strategy
BEACTICA THERAPEUTICS AB
participó en un
FP7:
Objective: To find and produce novel target compounds against the influenza virus. Influenza A capsid protein is the target since it does no...
Financiado
Financiado
* No se disponen de datos de la empresa actual.